- New International Market Now Protected for Enhanced Dermatology Products
LAS VEGAS, Aug. 20 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)
(Website: http://www.skinvisible.com), the developers of Invisicare, a
proprietary polymer delivery system for topically applied dermatology
products, is pleased to announce that it has been granted a comprehensive
patent in India. The patent granted protects Invisicare in the areas of
'Topical Composition', 'Topical Composition Precursor', and 'Methods for
Manufacturing and Using'.
These key patent components now allow for the protected manufacturing,
marketing and distribution of Skinvisible's Invisicare technology and its
formulated products in India. The key advantage of products formulated with
Invisicare is its unique ability to hold active ingredients on the skin for
extended periods of time while resisting wash-off, rub-off and perspiration.
It has the ability to enhance topical skincare products, give an extended life
to products coming off patent and be part of new formulations for
over-the-counter and prescription dermatology products.
"With a population of over 1.1 billion people, India will be a key market
for Skinvisible," said Mr. Terry Howlett, President and CEO of Skinvisible.
"This patent approval informs our potential licensees that we are committed to
protect our Intellectual Property as we work together to license our
proprietary dermatology products in India and elsewhere. Skinvisible has
filed for patent protection worldwide for Invisicare in order to meet the
demands of our domestic and international pharmaceutical & cosmeceutical
This is the first patent approved in India for Skinvisible. The Company
is also seeking patent protection for its dermatology products formulated with
Invisicare for this country. Along with its domestic patents pending in the
U.S. and Canada, additional international patents are pending for both
Invisicare and products formulated with Skinvisible's delivery system
Skinvisible has patented its technology and trademarked its polymer
delivery system Invisicare(R). Invisicare is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time. They are non-occlusive and allow normal skin respiration and
perspiration while moisturizing and protecting against exposure from a wide
variety of environmental irritants. See: www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose
primary business objective is to license its proprietary formulations with
Invisicare(R) to pharmaceutical and cosmeceutical companies as well as
assisting companies in revitalizing or enhancing their existing skin care
products. Skinvisible receives a combination of research and development fees,
upfront license fees, and ongoing royalties for the life of the Invisicare
patent. See: http://www.skinvisible.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending June 30, 2007).
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc.
For further information:
For further information: Terry Howlett, President-CEO of Skinvisible
Pharmaceuticals, Inc., +1-702-433-7154, email@example.com Web Site: